More than 30 distinct genomic loci are involved in the genetic susceptibility to CD.4 An infection or environmental factor may trigger or aggravate the disease.5 CD is treated with corticosteroids (CSs), immunomodulatory agents, and “biologic therapies,” including anti-TNF-α antibodies, vedolizumab, and ustekinumab.6-9 The standard anti-inflammatory regimen, however, does not halt disease progression.10 The CD remission rates must be improved, and recurrences must be reduced. Here, TNF is linked to Cowden disease.